Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Schumann (Basel, Switzerland), M. Tamm (Basel, Switzerland), K. Kostikas (Basel, Switzerland), D. Stolz (Basel, Switzerland). Stability of the eosinophilic phenotype in stable and exacerbated COPD. 5477

Member's Comments

No comment yet.

Related content which might interest you: Cellular inflammatory pattern in induced sputum among patients with stable moderate or severe asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Distribution of the cellular inflammatory pattern in induced sputum in an eosinophilic severe asthma population. Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Characterization of asthmatics displaying the functional phenotype of COPD Source: Annual Congress 2008 - Understanding airway inflammation Year: 2008 Can NPT be used to distinguish eosinophilic inflammatory phenotypes in COPD? Source: International Congress 2016 – What's new in biomarker analysis? Year: 2016 Upper airway symptoms associate with the eosinophilic phenotype of COPD Source: ERJ Open Res, 7 (3) 00184-2021; 10.1183/23120541.00184-2021 Year: 2021 Chronic sputum production and airway inflammation in COPD in the stable state and at exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 442s Year: 2005 The comparison of eosinophilic and non-eosinophilic  stable COPD patients Source: International Congress 2017 – Markers of COPD progression Year: 2017 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017 Relation of inflammatory process with COPD phenotype Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Increased sputum B cells in severe eosinophilic asthma: a local auto-inflammatory process Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics Year: 2018 Characterisation of the neutrophilic asthma phenotype over time. Source: Virtual Congress 2020 – Phenotypes of obstructive diseases Year: 2020 Mepolizumab improves activity limitation in severe eosinophilic asthma Source: International Congress 2017 – Notable abstracts in asthma Year: 2017 Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Evidence of a distinct phenotype of adult onset asthma characterized by an airway neutrophilia and poor response to inhaled corticosteroids Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Eicosanoids and eosinophilic inflammation of airways in stable COPD. Source: International Congress 2018 – COPD: immune regulation and therapeutic targets Year: 2018 Inflammatory mediators in eosinophilic COPD phenotype and asthma with fixed airflow obstruction Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Inflammatory cells composition of bronchial brush-biopsies in dependence on infectional agent species at COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 94s Year: 2005 Inflammatory cells composition of bronchial brush-biopsies in dependence on infectional agent species at COPD exacerbation Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Mepolizumab improves small airway function in severe eosinophilic asthma Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions Year: 2018 Characterization of COPD phenotype: comparison of the perceptual response to exercise in emphysema and chronic bronchitis patients Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008